Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 406Carcinoma, Non-Small-Cell Lung 147Urinary Bladder Neoplasms 87Breast Neoplasms 84Cholangiocarcinoma 82Lung Neoplasms 78Neoplasm Metastasis 67Neoplasms 64Biliary Tract Neoplasms 58Nasopharyngeal Carcinoma 53Ovarian Neoplasms 46Sarcoma 43Recurrence 39Gallbladder Neoplasms 39Hodgkin Disease 34Lymphoma, Large B-Cell, Diffuse 33Lymphoma 32Carcinoma, Transitional Cell 29Bile Duct Neoplasms 24Adenocarcinoma 23Fallopian Tube Neoplasms 19Carcinoma, Hepatocellular 19Adenocarcinoma of Lung 18Triple Negative Breast Neoplasms 17Lymphoma, Non-Hodgkin 17Liver Neoplasms 17Nasopharyngeal Neoplasms 16Lymphoma, Extranodal NK-T-Cell 16Carcinoma 16Non-Muscle Invasive Bladder Neoplasms 15

Interventions

nimotuzumab 2Gemcitabine 2surufatinib 1S 1 (combination) 1Radiofrequency Ablation 1Oxaliplatin 1Mass Screening 1Leucovorin 1Irinotecan 1Hematologic Tests 1Fluorouracil 1Blood Specimen Collection 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Pancreatic cancer, adult × Gemcitabine × Clear all
NCT07436741 2026-02-27

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 3 Not yet recruiting
106 enrolled
Gastrointestinal

Pancreatic cancer, adult

NCT06584227 2025-12-08

ACPC

Jinling Hospital, China

Phase 2 Recruiting
45 enrolled
Gastrointestinal

Pancreatic cancer, adult, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡